Gambro (Sweden) maintains lead in world dialysis market
This article was originally published in Clinica
Gambro (Sweden) holds around 18% of the SKr 35,000 million ($5,000 million) world dialysis products market, according to the company's 1994 annual report. Renal care sales of SKr 6,389 million accounted for just over 65% of total 1994 sales of SKr 9,807 million (see Clinica No 646, p 11).
You may also be interested in...
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.
No device-related warning letters were released by the US FDA the week of 19 February.
Complex generics and value added medicines share common challenges on harmonization of regulation, lack of incentives and clarity of guidelines, heard delegates to Medicines for Europe’s Regulatory & Scientific Affairs conference.